Cargando…
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/ https://www.ncbi.nlm.nih.gov/pubmed/27239522 http://dx.doi.org/10.1016/j.dadm.2015.09.001 |
_version_ | 1782433679154348032 |
---|---|
author | Mattsson, Niklas Carrillo, Maria C. Dean, Robert A. Devous, Michael D. Nikolcheva, Tania Pesini, Pedro Salter, Hugh Potter, William Z. Sperling, Reisa S. Bateman, Randall J. Bain, Lisa J. Liu, Enchi |
author_facet | Mattsson, Niklas Carrillo, Maria C. Dean, Robert A. Devous, Michael D. Nikolcheva, Tania Pesini, Pedro Salter, Hugh Potter, William Z. Sperling, Reisa S. Bateman, Randall J. Bain, Lisa J. Liu, Enchi |
author_sort | Mattsson, Niklas |
collection | PubMed |
description | The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts. |
format | Online Article Text |
id | pubmed-4879481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-48794812016-05-27 Revolutionizing Alzheimer's disease and clinical trials through biomarkers Mattsson, Niklas Carrillo, Maria C. Dean, Robert A. Devous, Michael D. Nikolcheva, Tania Pesini, Pedro Salter, Hugh Potter, William Z. Sperling, Reisa S. Bateman, Randall J. Bain, Lisa J. Liu, Enchi Alzheimers Dement (Amst) Diagnostic Assessment & Prognosis The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts. Elsevier 2015-10-03 /pmc/articles/PMC4879481/ /pubmed/27239522 http://dx.doi.org/10.1016/j.dadm.2015.09.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Diagnostic Assessment & Prognosis Mattsson, Niklas Carrillo, Maria C. Dean, Robert A. Devous, Michael D. Nikolcheva, Tania Pesini, Pedro Salter, Hugh Potter, William Z. Sperling, Reisa S. Bateman, Randall J. Bain, Lisa J. Liu, Enchi Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
title | Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
title_full | Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
title_fullStr | Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
title_full_unstemmed | Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
title_short | Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
title_sort | revolutionizing alzheimer's disease and clinical trials through biomarkers |
topic | Diagnostic Assessment & Prognosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/ https://www.ncbi.nlm.nih.gov/pubmed/27239522 http://dx.doi.org/10.1016/j.dadm.2015.09.001 |
work_keys_str_mv | AT mattssonniklas revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT carrillomariac revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT deanroberta revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT devousmichaeld revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT nikolchevatania revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT pesinipedro revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT salterhugh revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT potterwilliamz revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT sperlingreisas revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT batemanrandallj revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT bainlisaj revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers AT liuenchi revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers |